Publicação: Cytostatic in vitro Effects of DTCM-Glutarimide on Bladder Carcinoma Cells
Carregando...
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Asian Pacific Organization Cancer Prevention
Tipo
Artigo
Direito de acesso
Acesso aberto
Resumo
Bladder cancer is a common malignancy worldwide. Despite the increased use of cisplatin-based combination therapy, the outcomes for patients with advanced disease remain poor. Recently, altered activation of the PI3K/Akt/mTOR pathway has been associated with reduced patient survival and advanced stage of bladder cancer, making its upstream or downstream components attractive targets for therapeutic intervention. In the present study, we showed that treatment with DTCM-glutaramide, a piperidine that targets PDK1, results in reduced proliferation, diminished cell migration and G1 arrest in 5637 and T24 bladder carcinoma cells. Conversely, no apoptosis, necrosis or autophagy were detected after treatment, suggesting that reduced cell numbers in vitro are a result of diminished proliferation rather than cell death. Furthermore previous exposure to 10 mu g/ml DTCM-glutarimide sensitized both cell lines to ionizing radiation. Although more studies are needed to corroborate our findings, our results indicate that PDK1 may be useful as a therapeutic target to prevent progression and abnormal tissue dissemination of urothelial carcinomas.
Descrição
Palavras-chave
Urothelial cancer, PI3K/Akt/mTOR pathway, molecular target, therapy
Idioma
Inglês
Como citar
Asian Pacific Journal of Cancer Prevention. Gyeonggi-do: Asian Pacific Organization Cancer Prevention, v. 13, n. 5, p. 1957-1962, 2012.
